1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,000 | 0,000 | 13.07. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Diagnostear Technologies Inc: Diagnostear analyzes TeaRx, enzyme immunoassay | 1 | Stockwatch | ||
| Do | DiagnosTear Technologies Inc.: DiagnosTear Announces Interim Clinical Study Results Demonstrating Excellent Correlation Between TeaRx Red Eye and Quantitative ELISA Testing | 408 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - July 9, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), an innovator in point-of-care ocular diagnostics... ► Artikel lesen | |
| 05.06. | Diagnostear Technologies Inc: Diagnostear publishes TeaRx dry-eye study results | 3 | Stockwatch | ||
| DIAGNOSTEAR TECHNOLOGIES Aktie jetzt für 0€ handeln | |||||
| 05.06. | DiagnosTear Technologies Inc.: DiagnosTear Achieves Major Scientific Milestone with Publication of TeaRx Clinical Study in Current Eye Research Journal | 452 | Newsfile | Publication in a leading peer-reviewed ophthalmology journal further validates TeaRx as a novel point-of-care platform for diagnosis, patient stratification, and prediction of responsiveness to... ► Artikel lesen | |
| 15.05. | Bahnbrechende KI: Ohne Nadeln zum Blutbild! | bullVestor | |||
| 12.05. | DiagnosTear Technologies Inc.: DiagnosTear Secures Exclusive Global Rights to CLARIFY Eye Imaging Platform for Needle-Free Blood Diagnostics | 647 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - May 12, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a leader in rapid, eye-based diagnostic technologies... ► Artikel lesen | |
| 08.05. | Diagnostear Technologies Inc: Diagnostear shareholders approve all matters at AGM | 1 | Stockwatch | ||
| 07.05. | DiagnosTear Technologies Inc.: DiagnosTear Technologies Inc. Announces Results of AGM | 381 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - May 7, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company") is pleased to announce results of its annual general... ► Artikel lesen | |
| 05.05. | Diagnostear Technologies Inc: Diagnostear Technologies extends warrants | 17 | Stockwatch | ||
| 21.04. | DiagnosTear Technologies Inc.: DiagnosTear Technologies Inc. Announces Adoption of Semi-Annual Reporting | 615 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - April 21, 2026) - DiagnosTear Technologies Inc. ("DiagnosTear" or the "Company") announces that it has adopted a semi-annual financial reporting ("SAR")... ► Artikel lesen | |
| 26.02. | DiagnosTear Technologies Inc.: DiagnosTear Announces Regulatory Approvals in France and Study Initiation with AlyaTec for TeaRx Red Eye | 506 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care... ► Artikel lesen | |
| 21.02. | Diagnostear Technologies Inc: Diagnostear signs U.K. LOI with Hanson Medical | 9 | Stockwatch | ||
| 20.02. | DiagnosTear Technologies Inc.: DiagnosTear Advances UK Market Entry Through Commercial Collaboration with Hanson Medical | 979 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - February 20, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a developer of rapid point-of-care diagnostics... ► Artikel lesen | |
| 22.01. | Diagnostear Technologies Inc: Diagnostear Technologies moves to expand in India | 2 | Stockwatch | ||
| 22.01. | DiagnosTear Technologies Inc.: DiagnosTear Signs Letter of Intent to Advance Commercial Expansion of TeaRx in India | 459 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 22, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), an innovator in point-of-care ocular diagnostics... ► Artikel lesen | |
| 17.01. | Diagnostear Technologies Inc: Diagnostear receives interim clinical results for TeaRx | 4 | Stockwatch | ||
| 17.01. | DiagnosTear Technologies Inc.: DiagnosTear Announces Interim Clinical Results Indicating High Efficiency from TeaRx Red Eye | 867 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - January 16, 2026) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care... ► Artikel lesen | |
| 18.12.25 | DiagnosTear Technologies Inc.: DiagnosTear Signs Non-Binding Term Sheet with Sheba Impact and Ramot to Exclusively License New Eye Imaging Technology, CLARIFY, Enabling Needle-Free Blood Count | 848 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - December 17, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a leader in rapid eye based diagnostic technologies... ► Artikel lesen | |
| 09.12.25 | DiagnosTear Technologies Inc. - Confirmation of No Material Change | 597 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - December 9, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular... ► Artikel lesen | |
| 02.12.25 | DiagnosTear Technologies Inc.: DiagnosTear Announces Clinical Study with AlyaTec to Advance Analytical Validation and FDA Submission Pathway of TeaRx Red Eye Diagnostic Test | 577 | Newsfile | Vancouver, British Columbia--(Newsfile Corp. - December 2, 2025) - DiagnosTear Technologies Inc. (CSE: DTR) (FSE: X8F) ("DiagnosTear" or the "Company"), a fast-growing innovator in point-of-care ocular... ► Artikel lesen |
1 2 Weiter >>
25 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| FRESENIUS | 41,690 | -2,07 % | DAX nach Rekord tiefer: Börsen-Beben in Südkorea - Bayer, Rheinmetall, Fresenius und Kion ... | Beim deutschen Leitindex zeichnet sich am Dienstag ein schwächerer Start in den Handelstag ab. Schlechte Vorgaben aus Asien belasten den DAX. Während der Nikkei zur Stunde rund zwei Prozent verliert... ► Artikel lesen | |
| SIEMENS HEALTHINEERS | 35,560 | +2,80 % | UBS stuft Siemens Healthineers auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat das Kursziel für Siemens Healthineers von 51 auf 38 Euro gesenkt, aber die Einstufung auf "Neutral" belassen. Mehrere Risikofaktoren belasteten... ► Artikel lesen | |
| CARL ZEISS MEDITEC | 31,560 | +3,14 % | BERNSTEIN RESEARCH stuft CARL ZEISS MEDITEC AG auf 'Neutral' | NEW YORK (dpa-AFX Analyser) - Das US-Analysehaus Bernstein Research hat Carl Zeiss Meditec mit einem Kursziel von 26,10 Euro auf "Market-Perform" belassen. Dies schrieb Analystin Susannah Ludwig am... ► Artikel lesen | |
| INTUITIVE SURGICAL | 358,20 | +0,14 % | TD Cowen cuts Intuitive Surgical stock price target on valuation | ||
| DRAEGERWERK | 85,20 | +1,67 % | EQS-AFR: Drägerwerk AG & Co. KGaA: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114, 115, 117 WpHG | EQS Vorabbekanntmachung Finanzberichte: Drägerwerk AG & Co. KGaA
/ Vorabbekanntmachung über die Veröffentlichung von Rechnungslegungsberichten
Drägerwerk AG & Co. KGaA: Vorabbekanntmachung... ► Artikel lesen | |
| MEDTRONIC | 73,70 | +0,38 % | Medtronic warns on Harmony transcatheter pulmonary valve delivery system | ||
| THERMO FISHER | 464,20 | -0,04 % | Persistence Market Research Pvt. Ltd.: Cell Culture Media Market worth $12.9 billion by 2033: Biologics Manufacturing and Cell Therapy Expansion Accelerate Growth for Avantor, Thermo Fisher Scientific, and Lonza Group AG | LONDON, July 8, 2026 /PRNewswire/ -- Persistence Market Research, a leading management consulting firm, has released this update on the cell culture media market. These specialized nutrient... ► Artikel lesen | |
| TELADOC HEALTH | 8,458 | -0,17 % | Teladoc (TDOC) Rises Higher Than Market: Key Facts | ||
| HIMS & HERS HEALTH | 29,600 | -2,05 % | Truist reiterates Hold on Hims and Hers stock, $23 target on peptide uncertainty | ||
| FRESENIUS MEDICAL CARE | 42,940 | +2,41 % | JPMORGAN stuft FMC FRESENIUS MEDICAL CARE AG auf 'Underweight' | NEW YORK (dpa-AFX Analyser) - Die US-Bank JPMorgan hat FMC auf "Underweight" mit einem Kursziel von 37,40 Euro belassen. Aus neuesten Daten zu Nierenerkrankungen im Endstadium gehe hervor, dass immer... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 69,63 | -0,01 % | Raymond James initiates BrightSpring Health stock with outperform rating | ||
| HEARTFLOW | 26,160 | 0,00 % | Heartflow, Inc.: New Data at SCCT 2026 Reinforce Heartflow Plaque Analysis as the Standard for AI-Powered Coronary Artery Disease Management | ||
| BILLIONTOONE | 123,25 | 0,00 % | BillionToOne, Inc.: BillionToOne Reports Fourth Quarter and Full Year 2025 Results and Raises 2026 Revenue Guidance | MENLO PARK, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that... ► Artikel lesen | |
| ALIGNMENT HEALTHCARE | 20,380 | 0,00 % | Kaplan Fox & Kilsheimer LLP: Kaplan Fox Alerts Investors of Alignment Healthcare, Inc. (ALHC) to an Investigation of Potential Securities Law Violations | New York, New York--(Newsfile Corp. - July 10, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against Alignment Healthcare, Inc. ("Alignment Healthcare" or... ► Artikel lesen | |
| PROGYNY | 31,990 | +0,03 % | KeyBanc raises Progyny stock price target on utilization strength |
DIAGNOSTEAR TECHNOLOGIES INC gehört der Branche Gesundheitswesen an. Die relative Kursveränderung beträgt aktuell +1,69 % bei einem Aktienkurs von 0,180 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DIAGNOSTEAR TECHNOLOGIES INC finden Sie auf Wallstreet Online.